USA Financial Formulas Acquires New Position in Illumina, Inc. (NASDAQ:ILMN)

USA Financial Formulas purchased a new stake in shares of Illumina, Inc. (NASDAQ:ILMN - Free Report) during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor purchased 10,833 shares of the life sciences company's stock, valued at approximately $1,448,000. Illumina makes up about 0.2% of USA Financial Formulas' investment portfolio, making the stock its 17th biggest position.

Several other institutional investors have also bought and sold shares of the business. Versant Capital Management Inc increased its position in shares of Illumina by 153.7% during the 4th quarter. Versant Capital Management Inc now owns 241 shares of the life sciences company's stock valued at $32,000 after purchasing an additional 146 shares during the last quarter. TD Private Client Wealth LLC raised its stake in shares of Illumina by 58.5% in the third quarter. TD Private Client Wealth LLC now owns 382 shares of the life sciences company's stock valued at $50,000 after acquiring an additional 141 shares during the period. Massmutual Trust Co. FSB ADV raised its stake in shares of Illumina by 65.1% in the third quarter. Massmutual Trust Co. FSB ADV now owns 426 shares of the life sciences company's stock valued at $56,000 after acquiring an additional 168 shares during the period. Itau Unibanco Holding S.A. bought a new stake in shares of Illumina in the 2nd quarter worth about $61,000. Finally, Private Trust Co. NA boosted its stake in shares of Illumina by 81.2% during the 3rd quarter. Private Trust Co. NA now owns 473 shares of the life sciences company's stock worth $62,000 after purchasing an additional 212 shares during the period. Institutional investors own 89.42% of the company's stock.

Wall Street Analyst Weigh In

ILMN has been the topic of a number of recent analyst reports. Barclays increased their price objective on shares of Illumina from $135.00 to $145.00 and gave the stock an "equal weight" rating in a research report on Tuesday, November 5th. TD Cowen raised their price target on Illumina from $166.00 to $177.00 and gave the stock a "buy" rating in a research note on Tuesday, November 5th. Royal Bank of Canada upped their price objective on Illumina from $252.00 to $254.00 and gave the company an "outperform" rating in a research report on Tuesday, November 5th. HSBC upgraded Illumina from a "hold" rating to a "buy" rating and set a $180.00 target price for the company in a research report on Thursday, October 17th. Finally, JPMorgan Chase & Co. upped their price target on shares of Illumina from $125.00 to $140.00 and gave the stock a "neutral" rating in a report on Tuesday, November 5th. Eight equities research analysts have rated the stock with a hold rating, eleven have given a buy rating and two have issued a strong buy rating to the company's stock. According to data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and a consensus target price of $165.63.

Illumina Stock Up 0.5 %

ILMN traded up $0.74 on Thursday, hitting $136.93. The company had a trading volume of 765,683 shares, compared to its average volume of 1,676,793. The stock has a market capitalization of $21.72 billion, a price-to-earnings ratio of -13.78 and a beta of 1.11. The company has a debt-to-equity ratio of 0.94, a quick ratio of 1.85 and a current ratio of 2.43. The stock has a fifty day moving average price of $140.55 and a 200-day moving average price of $133.10. Illumina, Inc. has a 12-month low of $100.08 and a 12-month high of $156.66.

Illumina (NASDAQ:ILMN - Get Free Report) last issued its quarterly earnings data on Monday, November 4th. The life sciences company reported $1.14 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.88 by $0.26. Illumina had a negative net margin of 36.10% and a positive return on equity of 7.29%. The firm had revenue of $1.08 billion for the quarter, compared to the consensus estimate of $1.08 billion. During the same quarter in the previous year, the firm earned $0.33 EPS. The company's quarterly revenue was down 3.5% compared to the same quarter last year. Analysts predict that Illumina, Inc. will post 4.11 EPS for the current fiscal year.

Illumina Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.